TRIB3 Links Endoplasmic Reticulum Stress to Impaired Efferocytosis in Atherosclerosis.

backgroundDefective macrophage efferocytosis is a key driver of chronic nonresolving inflammation in dyslipidemia-associated diseases, such as obesity and atherosclerosis. However, the mechanism by which intracellular lipid accumulation impairs macrophage efferocytosis remains unclear. We hypothesized that lipid-induced endoplasmic reticulum (ER) stress mediates defective macrophage efferocytosis.

methodsBone marrow-derived macrophages were exposed to 7-ketocholesterol or palmitate to induce ER stress, and efferocytosis was quantified by measuring uptake of fluorescently labeled apoptotic cells with microscopy and flow cytometry. Key pathways were interrogated with pharmacological inhibitors, siRNA (silencing RNA), and in vivo models, including obese mice and in

resultsActivation of the ATF4 (activating transcription factor 4) branch of the ER stress pathway in lipid-loaded foamy macrophages led to upregulation of TRIB3, which triggered the downregulation of Rab27a, resulting in impaired focal exocytosis of intracellular membrane pools towards nascent, apoptotic cell-containing phagosomes. The resultant delay in phagosome closure stalled efferocytosis. In obese mice, this impairment was reversed using an ER stress-relieving chemical chaperone and via macrophage-specific knockdown of ATF4 or TRIB3. In atherosclerotic mice, hematopoietic cell-specific deletion of TRIB3 led to increased lesional efferocytosis, decreased plaque necrosis, and increased collagen, which are characteristic of stable plaques. In humans, TRIB3 expression was higher in vulnerable regions of carotid plaques, and macrophages from individuals carrying the gain-of-function TRIB3 Q84R risk variant expressed more TRIB3 and displayed decreased efferocytosis.

conclusionsLipid-induced ER stress impairs macrophage efferocytosis via activation of the ATF4-TRIB3-Rab27a signaling axis, leading to exacerbated plaque necrosis. Targeted disruption of TRIB3 signaling in macrophages represents a novel therapeutic approach to promote efferocytosis and stabilize atherosclerotic plaques.